Operating
Other Noncash Income (Expense)
United Therapeutics Other Noncash Income (Expense) decreased by 195.2% to -$32.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 680.5%, from -$4.10M to -$32.00M. Over 3 years (FY 2021 to FY 2025), Other Noncash Income (Expense) shows an upward trend with a -33.1% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryOther
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 6, 2026
How to read this metric
Large fluctuations may indicate one-time accounting adjustments or non-recurring non-cash events that require further investigation.
Detailed definition
This category aggregates various non-cash items that do not fit into standard categories like depreciation or stock-base...
Peer comparison
Standard line item in cash flow statements; peers use this to capture miscellaneous non-cash accounting impacts.
Metric ID:
operating_other_noncash_income_expenseHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$5.50M | -$31.00M | -$37.90M | $12.20M | -$46.80M | -$10.00M | -$7.90M | -$5.80M | $5.00M | $10.50M | $5.50M | $5.70M | $2.60M | -$4.10M | -$9.90M | $100.00K | $33.60M | -$32.00M |
| QoQ Change | — | -463.6% | -22.3% | +132.2% | -483.6% | +78.6% | +21.0% | +26.6% | +186.2% | +110.0% | -47.6% | +3.6% | -54.4% | -257.7% | -141.5% | +101.0% | >999% | -195.2% |
| YoY Change | — | — | — | — | -750.9% | +67.7% | +79.2% | -147.5% | +163.3% | +281.0% | — | — | -48.0% | -139.0% | -280.0% | -98.2% | >999% | -680.5% |
Range-$46.80M – $33.60M
CAGR+51.3%
Avg YoY Growth-30.1%
Median YoY Growth-73.1%
Other Noncash Income (Expense) at Other Companies
Frequently Asked Questions
- What is United Therapeutics's other noncash income (expense)?
- United Therapeutics (UTHR) reported other noncash income (expense) of -$32.00M in Q1 2026.
- How has United Therapeutics's other noncash income (expense) changed year-over-year?
- United Therapeutics's other noncash income (expense) decreased by 680.5% year-over-year, from -$4.10M to -$32.00M.
- What is the long-term trend for United Therapeutics's other noncash income (expense)?
- Over 3 years (2021 to 2025), United Therapeutics's other noncash income (expense) has grown at a -33.1% compound annual growth rate (CAGR), from -$65.90M to $19.70M.
- What does other noncash income (expense) mean?
- Miscellaneous non-cash income or expenses that impact net income but not cash flow.